Profile - To The Moon

kelvinnkq

hello

Posts · 6Posts · 6
Following · 0Following · 0
Followers · 0Followers · 0

- kelvinnkqkelvinnkq
  ·2020-12-26
  .
  Sorry, this post has been deleted
  1.58K Comment
  Like
  Share
  Report
- kelvinnkqkelvinnkq
  ·2020-12-26
  .
  Ocugen Establishes Vaccine Scientific Advisory Board
  MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceu
  Ocugen Establishes Vaccine Scientific Advisory Board
  969 Comment
  Like
  Share
  Report
- kelvinnkqkelvinnkq
  ·2020-12-26
  .
  Ocugen Establishes Vaccine Scientific Advisory Board
  MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceu
  Ocugen Establishes Vaccine Scientific Advisory Board
  1.45K Comment
  1
  Share
  Report
- kelvinnkqkelvinnkq
  ·2020-12-20
  .
  Sorry, this post has been deleted
  1.15K Comment
  Like
  Share
  Report
- kelvinnkqkelvinnkq
  ·2020-12-11
  .
  Nio joins Tesla and other rivals in rush to offer more shares in electric-vehicle companies
  Chinese electric-car company plans to sell up to 69 million fresh shares in U.S., after competitors
  Nio joins Tesla and other rivals in rush to offer more shares in electric-vehicle companies
  1.63K Comment
  1
  Share
  Report
- kelvinnkqkelvinnkq
  ·2020-12-09
  .
  LIVE MARKETS-FANG Index: Still getting its teeth "cleaned"
  * Major U.S. averages in positive territory; small caps outperform * S&P 500, Nasdaq hit new highs
  LIVE MARKETS-FANG Index: Still getting its teeth "cleaned"
  1.17K Comment
  1
  Share
  Report

Most Discussed

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3570084474850154","uuid":"3570084474850154","gmtCreate":1606991132190,"gmtModify":1607480421159,"name":"kelvinnkq","pinyin":"kelvinnkq","introduction":"","introductionEn":"","signature":"hello","avatar":"https://static.tigerbbs.com/a0288c00e3e6ae4f8970e539301a0694","hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","hatId":"ca_profile_frame_DWr5S1","hatName":"","vip":1,"status":2,"fanSize":2,"headSize":8,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":2,"name":"无畏虎","nameTw":"無畏虎","represent":"初生牛犊","factor":"发布3条非转发主帖,1条获得他人回复或点赞","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-3","templateUuid":"1026c425416b44e0aac28c11a0848493","name":" Tiger Idol","description":"Join the tiger community for 1500 days","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.12","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"93.26%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.76%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":1,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":339513985,"gmtCreate":1608915735947,"gmtModify":1704977042591,"author":{"id":"3570084474850154","authorId":"3570084474850154","name":"kelvinnkq","avatar":"https://static.tigerbbs.com/a0288c00e3e6ae4f8970e539301a0694","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570084474850154","idStr":"3570084474850154"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/339513985","repostId":"2093811655","repostType":2,"isVote":1,"tweetType":1,"viewCount":1581,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":339519790,"gmtCreate":1608915680110,"gmtModify":1704977042268,"author":{"id":"3570084474850154","authorId":"3570084474850154","name":"kelvinnkq","avatar":"https://static.tigerbbs.com/a0288c00e3e6ae4f8970e539301a0694","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570084474850154","idStr":"3570084474850154"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/339519790","repostId":"2093563596","repostType":2,"repost":{"id":"2093563596","kind":"news","pubTimestamp":1608768743,"share":"https://ttm.financial/m/news/2093563596?lang=&edition=fundamental","pubTime":"2020-12-24 08:12","market":"us","language":"en","title":"Ocugen Establishes Vaccine Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2093563596","media":"Ocugen","summary":"MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceu","content":"<html><body><article><p>MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies, today announced the appointment of a vaccine scientific advisory board comprised of leading academic and industry experts in the vaccine field to evaluate the clinical and regulatory path to approval in the US market of Bharat Biotech’s COVAXIN™, a whole-virion inactivated COVID-19 vaccine candidate to be co-developed by Ocugen and Bharat Biotech for the US market.</p><p>Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen remarked, “We are thrilled to welcome this group of esteemed thought leaders to the Ocugen team to assist in our co-development with Bharat Biotech of COVAXIN™. This unique yet traditional vaccine candidate is different from other options currently available in the US market with potentially broader coverage against multiple protein antigens of the virus.”</p><p>The vaccine scientific advisory board consists of:<strong> Satish Chandran, PhD, Wyeth Vaccines, Pfizer, Nucleonics, Somahlution </strong></p><p>Dr. Chandran founded Somahlution and is currently the Somahlution’s Chief Executive Officer and a member of the Board of Directors since inception in 2010. Prior to Somahlution he was the Chief Technology Officer at Pfizer Biotherapeutics and prior to that was the COO and CSO of Nucleonics, Inc. Satish started his biotech career at Apollon, Inc., headed the DNA vaccines at Wyeth Vaccines. He is a biotechnology veteran with nearly 30 years of leadership positions. Over the last 30 years, his career in biological research and development has spanned across academia and industry; early start up and mid-stage biotech companies and in large pharmaceutical companies. Satish’s passion and strength are in building and assembling teams and taking novel concepts and therapeutic strategies into products through development, regulatory approval, and commercialization. He is currently on the Board of Directors and serves as scientific advisor and consultant to several biotechnology companies.</p><p><strong> David Fajgenbaum, MD, MBA, MSc, FCPP, Translational Medicine &amp; Human Genetics, University of Pennsylvania, Founding Director of Center for Cytokine Storm Treatment &amp; Laboratory </strong></p><p>Dr. Fajgenbaum is an Assistant Professor of Medicine in Translational Medicine &amp; Human Genetics at the University of Pennsylvania, Director of the Penn Center for Cytokine Storm Treatment &amp; Laboratory, Executive Director of the Castleman Disease Collaborative Network, and Associate Director, Patient Impact for the Penn Orphan Disease Center. He is doing groundbreaking work to advance precision medicine for Castleman disease, a condition that he is battling as a physician, researcher, advocate, and patient. Combining omic technologies with machine learning and other bioinformatic tools, Dr. Fajgenbaum has discovered novel predictive biomarkers of treatment response and novel treatment approaches, including <a href=\"https://laohu8.com/S/AONE\">one</a> that is saving his life and others. Now, he is spreading this approach to other diseases such as COVID19.</p><p><strong> Bruce Forrest, MB, BS, MD, MBA, Wyeth Vaccines, Pfizer </strong></p><p>For over 25 years, Dr. Forrest worked as a pharmaceutical industry physician leading the global development of pharmaceuticals, vaccines, and biological drugs. As Senior Vice President at Wyeth Vaccines, Dr. Forrest was responsible for all late phase clinical and pharmaceutical science development activities for vaccines in the Wyeth pipeline, including Prevnar 13®; the meningococcal B vaccine (Trumemba®) and an early investigational Staphylococcus aureus vaccine. This role included managing a vaccines’ development organization situated in North Carolina and New York, responsible for all R&amp;D CMC and Manufacturing activities. In addition, Dr. Forrest was responsible for management and oversight of all Vaccines Clinical Research clinical trial and development activities globally with a dedicated vaccines clinical staff. He led the clinical activities supporting the market authorization for RotaShield®(EU), Prevnar®(Global), and FluMist®. Dr. Forrest also served as the Corporate Officer and Member of the Board of Wyeth K.K. during his tenure in Japan. He joined United Biomedical, Inc. in 1993 leading the earliest international clinical development of HIV vaccines, initiating clinical trials in China, Australia, and Thailand. At Chiron Corporation he was the global clinical team leader for a meningococcal C conjugate vaccine (Menjugate®). Dr. Forrest is an investment banker with a Westchester, NY based investment bank (Young America Capital, LLC) where he co-heads Life Sciences Investment Banking. He also owns an independent FINRA-registered investment advisory firm that is regulated by the State of New York (Aeolian Advisors Corp.).</p><p><strong> Catherine Pachuk, PhD, Chief Scientific Officer, Marizyme, Wyeth Vaccines, Pfizer and Coronavirologist, Vaccinologist </strong></p><p>Dr. Pachuk has over twenty-five years R&amp;D leadership experience in the pharmaceutical and biotech sectors with expertise in both drug, device, and vaccine development with significant experience in nucleic-acid based therapeutic platforms including ASO, RNAi and nucleic-acid based vaccines. Her key areas of therapeutic focus are viral diseases including Hepatitis B, Hepatitis C, and Coronavirus, metabolic disease, HCC, and indications associated with Ischemia Reperfusion Injury. She was involved in advancing multiple product candidates into the clinic and market including several first-in-man compounds. She received her Ph.D. in molecular virology from the University of Pennsylvania where she studied the molecular biology of coronaviruses. She also has a dual Regulatory Affairs Certificate from RAPS (Regulatory Affairs Professional Society) in Medical Devices and Pharmaceuticals.</p><p><strong> Harvey Rubin, MD, PhD, Professor of Microbiology and Infectious Diseases, U Pennsylvania </strong></p><p>Dr. Rubin is Professor of Medicine with secondary appointment as Professor of Computer Sciences at the University of Pennsylvania. The NIH, NSF, DARPA, the Global Alliance for TB Drug Discovery, and the Gates Foundation have funded his basic biochemical and genetic research in infectious diseases, resulting in more than 100 peer-reviewed papers. He served on national and international scientific review panels including the NIH, NSF, NASA Intelligent Systems Program, DARPA, and The Medical Research Council, South Africa. He was a member of the U.S. National Science Advisory Board for Biosecurity and the Dept. of Defense/National Academy of Sciences Biological Cooperative Threat Reduction Program. Dr. Rubin is the founder of Energize the Chain, a non-profit organization and GAVI INFUSE and funded partner that ensures the delivery of vaccines to people in the most remote regions of the world by utilizing power and connectivity in the private sector, such as that available at cell tower sites to power the refrigeration systems that are necessary to keep vaccines at the proper temperature.</p><p><strong> Susan Weiss, PhD, Professor of Microbiology, U Pennsylvania. Co-Director Coronavirus Research Center and Renowned Coronavirologist </strong></p><p>Dr. Weiss obtained her PhD in Microbiology and Molecular Genetics from Harvard University working on paramyxoviruses and did postdoctoral training in retroviruses at University of California, San Francisco with Mike Bishop and Harold Varmus. She moved to the University of Pennsylvania in 1980, where she is currently Professor and Vice Chair, Department of Microbiology and Co-director of the Penn Center for Research on Coronaviruses and Other Emerging Pathogens at the Perelman School of Medicine. She has worked on many aspects of coronavirus replication and pathogenesis over the last forty years, making contributions to understanding the basic biology as well as organ tropism and virulence. She has worked with murine coronavirus (MHV), MERS-CoV and most recently SARS-CoV-2. Her work for the last ten years has focused on coronavirus interaction with the host innate immune response and viral innate antagonists of double-stranded RNA induced antiviral pathways. Her other research interests include activation and antagonism of the antiviral oligoadenylate-ribonuclease L (OAS-RNase L) pathway, flavivirus- primarily Zika- virus-host interactions and pathogenic effects of host endogenous dsRNA.</p><p><strong> About Ocugen, Inc. </strong></p><p>Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with <a href=\"https://laohu8.com/S/AONE.U\">one</a> drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit www.ocugen.com.</p><p><strong> Cautionary Note on Forward-Looking Statements </strong></p><p>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.</p><p><strong> Ocugen Contact: </strong></p><p>Ocugen, Inc.</p><p>Sanjay Subramanian</p><p>Chief Financial Officer</p><p>ir@ocugen.com</p><p><strong> Media Contact: </strong></p><p>LaVoieHealthScience</p><p>Lisa DeScenza</p><p>ldescenza@lavoiehealthscience.com</p><p>+1 978-395-5970</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Establishes Vaccine Scientific Advisory Board</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Establishes Vaccine Scientific Advisory Board\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-12-24 08:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020122408220979acd0cf&s=b><strong>Ocugen</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020122408220979acd0cf&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020122408220979acd0cf&s=b","is_english":true,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2093563596","content_text":"MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies, today announced the appointment of a vaccine scientific advisory board comprised of leading academic and industry experts in the vaccine field to evaluate the clinical and regulatory path to approval in the US market of Bharat Biotech’s COVAXIN™, a whole-virion inactivated COVID-19 vaccine candidate to be co-developed by Ocugen and Bharat Biotech for the US market.Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen remarked, “We are thrilled to welcome this group of esteemed thought leaders to the Ocugen team to assist in our co-development with Bharat Biotech of COVAXIN™. This unique yet traditional vaccine candidate is different from other options currently available in the US market with potentially broader coverage against multiple protein antigens of the virus.”The vaccine scientific advisory board consists of: Satish Chandran, PhD, Wyeth Vaccines, Pfizer, Nucleonics, Somahlution Dr. Chandran founded Somahlution and is currently the Somahlution’s Chief Executive Officer and a member of the Board of Directors since inception in 2010. Prior to Somahlution he was the Chief Technology Officer at Pfizer Biotherapeutics and prior to that was the COO and CSO of Nucleonics, Inc. Satish started his biotech career at Apollon, Inc., headed the DNA vaccines at Wyeth Vaccines. He is a biotechnology veteran with nearly 30 years of leadership positions. Over the last 30 years, his career in biological research and development has spanned across academia and industry; early start up and mid-stage biotech companies and in large pharmaceutical companies. Satish’s passion and strength are in building and assembling teams and taking novel concepts and therapeutic strategies into products through development, regulatory approval, and commercialization. He is currently on the Board of Directors and serves as scientific advisor and consultant to several biotechnology companies. David Fajgenbaum, MD, MBA, MSc, FCPP, Translational Medicine & Human Genetics, University of Pennsylvania, Founding Director of Center for Cytokine Storm Treatment & Laboratory Dr. Fajgenbaum is an Assistant Professor of Medicine in Translational Medicine & Human Genetics at the University of Pennsylvania, Director of the Penn Center for Cytokine Storm Treatment & Laboratory, Executive Director of the Castleman Disease Collaborative Network, and Associate Director, Patient Impact for the Penn Orphan Disease Center. He is doing groundbreaking work to advance precision medicine for Castleman disease, a condition that he is battling as a physician, researcher, advocate, and patient. Combining omic technologies with machine learning and other bioinformatic tools, Dr. Fajgenbaum has discovered novel predictive biomarkers of treatment response and novel treatment approaches, including one that is saving his life and others. Now, he is spreading this approach to other diseases such as COVID19. Bruce Forrest, MB, BS, MD, MBA, Wyeth Vaccines, Pfizer For over 25 years, Dr. Forrest worked as a pharmaceutical industry physician leading the global development of pharmaceuticals, vaccines, and biological drugs. As Senior Vice President at Wyeth Vaccines, Dr. Forrest was responsible for all late phase clinical and pharmaceutical science development activities for vaccines in the Wyeth pipeline, including Prevnar 13®; the meningococcal B vaccine (Trumemba®) and an early investigational Staphylococcus aureus vaccine. This role included managing a vaccines’ development organization situated in North Carolina and New York, responsible for all R&D CMC and Manufacturing activities. In addition, Dr. Forrest was responsible for management and oversight of all Vaccines Clinical Research clinical trial and development activities globally with a dedicated vaccines clinical staff. He led the clinical activities supporting the market authorization for RotaShield®(EU), Prevnar®(Global), and FluMist®. Dr. Forrest also served as the Corporate Officer and Member of the Board of Wyeth K.K. during his tenure in Japan. He joined United Biomedical, Inc. in 1993 leading the earliest international clinical development of HIV vaccines, initiating clinical trials in China, Australia, and Thailand. At Chiron Corporation he was the global clinical team leader for a meningococcal C conjugate vaccine (Menjugate®). Dr. Forrest is an investment banker with a Westchester, NY based investment bank (Young America Capital, LLC) where he co-heads Life Sciences Investment Banking. He also owns an independent FINRA-registered investment advisory firm that is regulated by the State of New York (Aeolian Advisors Corp.). Catherine Pachuk, PhD, Chief Scientific Officer, Marizyme, Wyeth Vaccines, Pfizer and Coronavirologist, Vaccinologist Dr. Pachuk has over twenty-five years R&D leadership experience in the pharmaceutical and biotech sectors with expertise in both drug, device, and vaccine development with significant experience in nucleic-acid based therapeutic platforms including ASO, RNAi and nucleic-acid based vaccines. Her key areas of therapeutic focus are viral diseases including Hepatitis B, Hepatitis C, and Coronavirus, metabolic disease, HCC, and indications associated with Ischemia Reperfusion Injury. She was involved in advancing multiple product candidates into the clinic and market including several first-in-man compounds. She received her Ph.D. in molecular virology from the University of Pennsylvania where she studied the molecular biology of coronaviruses. She also has a dual Regulatory Affairs Certificate from RAPS (Regulatory Affairs Professional Society) in Medical Devices and Pharmaceuticals. Harvey Rubin, MD, PhD, Professor of Microbiology and Infectious Diseases, U Pennsylvania Dr. Rubin is Professor of Medicine with secondary appointment as Professor of Computer Sciences at the University of Pennsylvania. The NIH, NSF, DARPA, the Global Alliance for TB Drug Discovery, and the Gates Foundation have funded his basic biochemical and genetic research in infectious diseases, resulting in more than 100 peer-reviewed papers. He served on national and international scientific review panels including the NIH, NSF, NASA Intelligent Systems Program, DARPA, and The Medical Research Council, South Africa. He was a member of the U.S. National Science Advisory Board for Biosecurity and the Dept. of Defense/National Academy of Sciences Biological Cooperative Threat Reduction Program. Dr. Rubin is the founder of Energize the Chain, a non-profit organization and GAVI INFUSE and funded partner that ensures the delivery of vaccines to people in the most remote regions of the world by utilizing power and connectivity in the private sector, such as that available at cell tower sites to power the refrigeration systems that are necessary to keep vaccines at the proper temperature. Susan Weiss, PhD, Professor of Microbiology, U Pennsylvania. Co-Director Coronavirus Research Center and Renowned Coronavirologist Dr. Weiss obtained her PhD in Microbiology and Molecular Genetics from Harvard University working on paramyxoviruses and did postdoctoral training in retroviruses at University of California, San Francisco with Mike Bishop and Harold Varmus. She moved to the University of Pennsylvania in 1980, where she is currently Professor and Vice Chair, Department of Microbiology and Co-director of the Penn Center for Research on Coronaviruses and Other Emerging Pathogens at the Perelman School of Medicine. She has worked on many aspects of coronavirus replication and pathogenesis over the last forty years, making contributions to understanding the basic biology as well as organ tropism and virulence. She has worked with murine coronavirus (MHV), MERS-CoV and most recently SARS-CoV-2. Her work for the last ten years has focused on coronavirus interaction with the host innate immune response and viral innate antagonists of double-stranded RNA induced antiviral pathways. Her other research interests include activation and antagonism of the antiviral oligoadenylate-ribonuclease L (OAS-RNase L) pathway, flavivirus- primarily Zika- virus-host interactions and pathogenic effects of host endogenous dsRNA. About Ocugen, Inc. Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit www.ocugen.com. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. Ocugen Contact: Ocugen, Inc.Sanjay SubramanianChief Financial Officerir@ocugen.com Media Contact: LaVoieHealthScienceLisa DeScenzaldescenza@lavoiehealthscience.com+1 978-395-5970","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":969,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":339519487,"gmtCreate":1608915669149,"gmtModify":1704977041622,"author":{"id":"3570084474850154","authorId":"3570084474850154","name":"kelvinnkq","avatar":"https://static.tigerbbs.com/a0288c00e3e6ae4f8970e539301a0694","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570084474850154","idStr":"3570084474850154"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/339519487","repostId":"2093563596","repostType":2,"repost":{"id":"2093563596","kind":"news","pubTimestamp":1608768743,"share":"https://ttm.financial/m/news/2093563596?lang=&edition=fundamental","pubTime":"2020-12-24 08:12","market":"us","language":"en","title":"Ocugen Establishes Vaccine Scientific Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2093563596","media":"Ocugen","summary":"MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceu","content":"<html><body><article><p>MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies, today announced the appointment of a vaccine scientific advisory board comprised of leading academic and industry experts in the vaccine field to evaluate the clinical and regulatory path to approval in the US market of Bharat Biotech’s COVAXIN™, a whole-virion inactivated COVID-19 vaccine candidate to be co-developed by Ocugen and Bharat Biotech for the US market.</p><p>Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen remarked, “We are thrilled to welcome this group of esteemed thought leaders to the Ocugen team to assist in our co-development with Bharat Biotech of COVAXIN™. This unique yet traditional vaccine candidate is different from other options currently available in the US market with potentially broader coverage against multiple protein antigens of the virus.”</p><p>The vaccine scientific advisory board consists of:<strong> Satish Chandran, PhD, Wyeth Vaccines, Pfizer, Nucleonics, Somahlution </strong></p><p>Dr. Chandran founded Somahlution and is currently the Somahlution’s Chief Executive Officer and a member of the Board of Directors since inception in 2010. Prior to Somahlution he was the Chief Technology Officer at Pfizer Biotherapeutics and prior to that was the COO and CSO of Nucleonics, Inc. Satish started his biotech career at Apollon, Inc., headed the DNA vaccines at Wyeth Vaccines. He is a biotechnology veteran with nearly 30 years of leadership positions. Over the last 30 years, his career in biological research and development has spanned across academia and industry; early start up and mid-stage biotech companies and in large pharmaceutical companies. Satish’s passion and strength are in building and assembling teams and taking novel concepts and therapeutic strategies into products through development, regulatory approval, and commercialization. He is currently on the Board of Directors and serves as scientific advisor and consultant to several biotechnology companies.</p><p><strong> David Fajgenbaum, MD, MBA, MSc, FCPP, Translational Medicine &amp; Human Genetics, University of Pennsylvania, Founding Director of Center for Cytokine Storm Treatment &amp; Laboratory </strong></p><p>Dr. Fajgenbaum is an Assistant Professor of Medicine in Translational Medicine &amp; Human Genetics at the University of Pennsylvania, Director of the Penn Center for Cytokine Storm Treatment &amp; Laboratory, Executive Director of the Castleman Disease Collaborative Network, and Associate Director, Patient Impact for the Penn Orphan Disease Center. He is doing groundbreaking work to advance precision medicine for Castleman disease, a condition that he is battling as a physician, researcher, advocate, and patient. Combining omic technologies with machine learning and other bioinformatic tools, Dr. Fajgenbaum has discovered novel predictive biomarkers of treatment response and novel treatment approaches, including <a href=\"https://laohu8.com/S/AONE\">one</a> that is saving his life and others. Now, he is spreading this approach to other diseases such as COVID19.</p><p><strong> Bruce Forrest, MB, BS, MD, MBA, Wyeth Vaccines, Pfizer </strong></p><p>For over 25 years, Dr. Forrest worked as a pharmaceutical industry physician leading the global development of pharmaceuticals, vaccines, and biological drugs. As Senior Vice President at Wyeth Vaccines, Dr. Forrest was responsible for all late phase clinical and pharmaceutical science development activities for vaccines in the Wyeth pipeline, including Prevnar 13®; the meningococcal B vaccine (Trumemba®) and an early investigational Staphylococcus aureus vaccine. This role included managing a vaccines’ development organization situated in North Carolina and New York, responsible for all R&amp;D CMC and Manufacturing activities. In addition, Dr. Forrest was responsible for management and oversight of all Vaccines Clinical Research clinical trial and development activities globally with a dedicated vaccines clinical staff. He led the clinical activities supporting the market authorization for RotaShield®(EU), Prevnar®(Global), and FluMist®. Dr. Forrest also served as the Corporate Officer and Member of the Board of Wyeth K.K. during his tenure in Japan. He joined United Biomedical, Inc. in 1993 leading the earliest international clinical development of HIV vaccines, initiating clinical trials in China, Australia, and Thailand. At Chiron Corporation he was the global clinical team leader for a meningococcal C conjugate vaccine (Menjugate®). Dr. Forrest is an investment banker with a Westchester, NY based investment bank (Young America Capital, LLC) where he co-heads Life Sciences Investment Banking. He also owns an independent FINRA-registered investment advisory firm that is regulated by the State of New York (Aeolian Advisors Corp.).</p><p><strong> Catherine Pachuk, PhD, Chief Scientific Officer, Marizyme, Wyeth Vaccines, Pfizer and Coronavirologist, Vaccinologist </strong></p><p>Dr. Pachuk has over twenty-five years R&amp;D leadership experience in the pharmaceutical and biotech sectors with expertise in both drug, device, and vaccine development with significant experience in nucleic-acid based therapeutic platforms including ASO, RNAi and nucleic-acid based vaccines. Her key areas of therapeutic focus are viral diseases including Hepatitis B, Hepatitis C, and Coronavirus, metabolic disease, HCC, and indications associated with Ischemia Reperfusion Injury. She was involved in advancing multiple product candidates into the clinic and market including several first-in-man compounds. She received her Ph.D. in molecular virology from the University of Pennsylvania where she studied the molecular biology of coronaviruses. She also has a dual Regulatory Affairs Certificate from RAPS (Regulatory Affairs Professional Society) in Medical Devices and Pharmaceuticals.</p><p><strong> Harvey Rubin, MD, PhD, Professor of Microbiology and Infectious Diseases, U Pennsylvania </strong></p><p>Dr. Rubin is Professor of Medicine with secondary appointment as Professor of Computer Sciences at the University of Pennsylvania. The NIH, NSF, DARPA, the Global Alliance for TB Drug Discovery, and the Gates Foundation have funded his basic biochemical and genetic research in infectious diseases, resulting in more than 100 peer-reviewed papers. He served on national and international scientific review panels including the NIH, NSF, NASA Intelligent Systems Program, DARPA, and The Medical Research Council, South Africa. He was a member of the U.S. National Science Advisory Board for Biosecurity and the Dept. of Defense/National Academy of Sciences Biological Cooperative Threat Reduction Program. Dr. Rubin is the founder of Energize the Chain, a non-profit organization and GAVI INFUSE and funded partner that ensures the delivery of vaccines to people in the most remote regions of the world by utilizing power and connectivity in the private sector, such as that available at cell tower sites to power the refrigeration systems that are necessary to keep vaccines at the proper temperature.</p><p><strong> Susan Weiss, PhD, Professor of Microbiology, U Pennsylvania. Co-Director Coronavirus Research Center and Renowned Coronavirologist </strong></p><p>Dr. Weiss obtained her PhD in Microbiology and Molecular Genetics from Harvard University working on paramyxoviruses and did postdoctoral training in retroviruses at University of California, San Francisco with Mike Bishop and Harold Varmus. She moved to the University of Pennsylvania in 1980, where she is currently Professor and Vice Chair, Department of Microbiology and Co-director of the Penn Center for Research on Coronaviruses and Other Emerging Pathogens at the Perelman School of Medicine. She has worked on many aspects of coronavirus replication and pathogenesis over the last forty years, making contributions to understanding the basic biology as well as organ tropism and virulence. She has worked with murine coronavirus (MHV), MERS-CoV and most recently SARS-CoV-2. Her work for the last ten years has focused on coronavirus interaction with the host innate immune response and viral innate antagonists of double-stranded RNA induced antiviral pathways. Her other research interests include activation and antagonism of the antiviral oligoadenylate-ribonuclease L (OAS-RNase L) pathway, flavivirus- primarily Zika- virus-host interactions and pathogenic effects of host endogenous dsRNA.</p><p><strong> About Ocugen, Inc. </strong></p><p>Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with <a href=\"https://laohu8.com/S/AONE.U\">one</a> drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit www.ocugen.com.</p><p><strong> Cautionary Note on Forward-Looking Statements </strong></p><p>This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release.</p><p><strong> Ocugen Contact: </strong></p><p>Ocugen, Inc.</p><p>Sanjay Subramanian</p><p>Chief Financial Officer</p><p>ir@ocugen.com</p><p><strong> Media Contact: </strong></p><p>LaVoieHealthScience</p><p>Lisa DeScenza</p><p>ldescenza@lavoiehealthscience.com</p><p>+1 978-395-5970</p></article></body></html>","source":"tencent","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Establishes Vaccine Scientific Advisory Board</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Establishes Vaccine Scientific Advisory Board\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-12-24 08:12 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020122408220979acd0cf&s=b><strong>Ocugen</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative ...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020122408220979acd0cf&s=b\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2020122408220979acd0cf&s=b","is_english":true,"share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","article_id":"2093563596","content_text":"MALVERN, Pa., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Ocugen, Inc., (NASDAQ: OCGN), a leading biopharmaceutical company focused on discovering, developing and commercializing a pipeline of innovative therapies, today announced the appointment of a vaccine scientific advisory board comprised of leading academic and industry experts in the vaccine field to evaluate the clinical and regulatory path to approval in the US market of Bharat Biotech’s COVAXIN™, a whole-virion inactivated COVID-19 vaccine candidate to be co-developed by Ocugen and Bharat Biotech for the US market.Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder of Ocugen remarked, “We are thrilled to welcome this group of esteemed thought leaders to the Ocugen team to assist in our co-development with Bharat Biotech of COVAXIN™. This unique yet traditional vaccine candidate is different from other options currently available in the US market with potentially broader coverage against multiple protein antigens of the virus.”The vaccine scientific advisory board consists of: Satish Chandran, PhD, Wyeth Vaccines, Pfizer, Nucleonics, Somahlution Dr. Chandran founded Somahlution and is currently the Somahlution’s Chief Executive Officer and a member of the Board of Directors since inception in 2010. Prior to Somahlution he was the Chief Technology Officer at Pfizer Biotherapeutics and prior to that was the COO and CSO of Nucleonics, Inc. Satish started his biotech career at Apollon, Inc., headed the DNA vaccines at Wyeth Vaccines. He is a biotechnology veteran with nearly 30 years of leadership positions. Over the last 30 years, his career in biological research and development has spanned across academia and industry; early start up and mid-stage biotech companies and in large pharmaceutical companies. Satish’s passion and strength are in building and assembling teams and taking novel concepts and therapeutic strategies into products through development, regulatory approval, and commercialization. He is currently on the Board of Directors and serves as scientific advisor and consultant to several biotechnology companies. David Fajgenbaum, MD, MBA, MSc, FCPP, Translational Medicine & Human Genetics, University of Pennsylvania, Founding Director of Center for Cytokine Storm Treatment & Laboratory Dr. Fajgenbaum is an Assistant Professor of Medicine in Translational Medicine & Human Genetics at the University of Pennsylvania, Director of the Penn Center for Cytokine Storm Treatment & Laboratory, Executive Director of the Castleman Disease Collaborative Network, and Associate Director, Patient Impact for the Penn Orphan Disease Center. He is doing groundbreaking work to advance precision medicine for Castleman disease, a condition that he is battling as a physician, researcher, advocate, and patient. Combining omic technologies with machine learning and other bioinformatic tools, Dr. Fajgenbaum has discovered novel predictive biomarkers of treatment response and novel treatment approaches, including one that is saving his life and others. Now, he is spreading this approach to other diseases such as COVID19. Bruce Forrest, MB, BS, MD, MBA, Wyeth Vaccines, Pfizer For over 25 years, Dr. Forrest worked as a pharmaceutical industry physician leading the global development of pharmaceuticals, vaccines, and biological drugs. As Senior Vice President at Wyeth Vaccines, Dr. Forrest was responsible for all late phase clinical and pharmaceutical science development activities for vaccines in the Wyeth pipeline, including Prevnar 13®; the meningococcal B vaccine (Trumemba®) and an early investigational Staphylococcus aureus vaccine. This role included managing a vaccines’ development organization situated in North Carolina and New York, responsible for all R&D CMC and Manufacturing activities. In addition, Dr. Forrest was responsible for management and oversight of all Vaccines Clinical Research clinical trial and development activities globally with a dedicated vaccines clinical staff. He led the clinical activities supporting the market authorization for RotaShield®(EU), Prevnar®(Global), and FluMist®. Dr. Forrest also served as the Corporate Officer and Member of the Board of Wyeth K.K. during his tenure in Japan. He joined United Biomedical, Inc. in 1993 leading the earliest international clinical development of HIV vaccines, initiating clinical trials in China, Australia, and Thailand. At Chiron Corporation he was the global clinical team leader for a meningococcal C conjugate vaccine (Menjugate®). Dr. Forrest is an investment banker with a Westchester, NY based investment bank (Young America Capital, LLC) where he co-heads Life Sciences Investment Banking. He also owns an independent FINRA-registered investment advisory firm that is regulated by the State of New York (Aeolian Advisors Corp.). Catherine Pachuk, PhD, Chief Scientific Officer, Marizyme, Wyeth Vaccines, Pfizer and Coronavirologist, Vaccinologist Dr. Pachuk has over twenty-five years R&D leadership experience in the pharmaceutical and biotech sectors with expertise in both drug, device, and vaccine development with significant experience in nucleic-acid based therapeutic platforms including ASO, RNAi and nucleic-acid based vaccines. Her key areas of therapeutic focus are viral diseases including Hepatitis B, Hepatitis C, and Coronavirus, metabolic disease, HCC, and indications associated with Ischemia Reperfusion Injury. She was involved in advancing multiple product candidates into the clinic and market including several first-in-man compounds. She received her Ph.D. in molecular virology from the University of Pennsylvania where she studied the molecular biology of coronaviruses. She also has a dual Regulatory Affairs Certificate from RAPS (Regulatory Affairs Professional Society) in Medical Devices and Pharmaceuticals. Harvey Rubin, MD, PhD, Professor of Microbiology and Infectious Diseases, U Pennsylvania Dr. Rubin is Professor of Medicine with secondary appointment as Professor of Computer Sciences at the University of Pennsylvania. The NIH, NSF, DARPA, the Global Alliance for TB Drug Discovery, and the Gates Foundation have funded his basic biochemical and genetic research in infectious diseases, resulting in more than 100 peer-reviewed papers. He served on national and international scientific review panels including the NIH, NSF, NASA Intelligent Systems Program, DARPA, and The Medical Research Council, South Africa. He was a member of the U.S. National Science Advisory Board for Biosecurity and the Dept. of Defense/National Academy of Sciences Biological Cooperative Threat Reduction Program. Dr. Rubin is the founder of Energize the Chain, a non-profit organization and GAVI INFUSE and funded partner that ensures the delivery of vaccines to people in the most remote regions of the world by utilizing power and connectivity in the private sector, such as that available at cell tower sites to power the refrigeration systems that are necessary to keep vaccines at the proper temperature. Susan Weiss, PhD, Professor of Microbiology, U Pennsylvania. Co-Director Coronavirus Research Center and Renowned Coronavirologist Dr. Weiss obtained her PhD in Microbiology and Molecular Genetics from Harvard University working on paramyxoviruses and did postdoctoral training in retroviruses at University of California, San Francisco with Mike Bishop and Harold Varmus. She moved to the University of Pennsylvania in 1980, where she is currently Professor and Vice Chair, Department of Microbiology and Co-director of the Penn Center for Research on Coronaviruses and Other Emerging Pathogens at the Perelman School of Medicine. She has worked on many aspects of coronavirus replication and pathogenesis over the last forty years, making contributions to understanding the basic biology as well as organ tropism and virulence. She has worked with murine coronavirus (MHV), MERS-CoV and most recently SARS-CoV-2. Her work for the last ten years has focused on coronavirus interaction with the host innate immune response and viral innate antagonists of double-stranded RNA induced antiviral pathways. Her other research interests include activation and antagonism of the antiviral oligoadenylate-ribonuclease L (OAS-RNase L) pathway, flavivirus- primarily Zika- virus-host interactions and pathogenic effects of host endogenous dsRNA. About Ocugen, Inc. Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing transformative therapies to cure blindness diseases. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit www.ocugen.com. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (the “SEC”), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. Ocugen Contact: Ocugen, Inc.Sanjay SubramanianChief Financial Officerir@ocugen.com Media Contact: LaVoieHealthScienceLisa DeScenzaldescenza@lavoiehealthscience.com+1 978-395-5970","news_type":1,"symbols_score_info":{"OCGN":0.9}},"isVote":1,"tweetType":1,"viewCount":1453,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":330090835,"gmtCreate":1608395097227,"gmtModify":1704974747134,"author":{"id":"3570084474850154","authorId":"3570084474850154","name":"kelvinnkq","avatar":"https://static.tigerbbs.com/a0288c00e3e6ae4f8970e539301a0694","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570084474850154","idStr":"3570084474850154"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/330090835","repostId":"2091642808","repostType":2,"isVote":1,"tweetType":1,"viewCount":1154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":395646473,"gmtCreate":1607656265992,"gmtModify":1704971557301,"author":{"id":"3570084474850154","authorId":"3570084474850154","name":"kelvinnkq","avatar":"https://static.tigerbbs.com/a0288c00e3e6ae4f8970e539301a0694","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570084474850154","idStr":"3570084474850154"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/395646473","repostId":"1165742728","repostType":2,"repost":{"id":"1165742728","kind":"news","pubTimestamp":1607655676,"share":"https://ttm.financial/m/news/1165742728?lang=&edition=fundamental","pubTime":"2020-12-11 11:01","market":"us","language":"en","title":"Nio joins Tesla and other rivals in rush to offer more shares in electric-vehicle companies","url":"https://stock-news.laohu8.com/highlight/detail?id=1165742728","media":"marketwatch","summary":"Chinese electric-car company plans to sell up to 69 million fresh shares in U.S., after competitors ","content":"<p>Chinese electric-car company plans to sell up to 69 million fresh shares in U.S., after competitors Tesla, XPeng and Li Auto announced stock-sale plans.</p>\n<p>Electric-car companies may be selling more shares than cars at the end of 2020.</p>\n<p>Amid an explosion in stock prices of electric-vehicle manufacturers, Chinese EV company Nio Inc.NIO,+2.75%announced Thursday afternoon that it plans to sell at least 60 million fresh American depositary shares, with an additional 9 million shares available to underwriters. Nio stock dropped more than 4% in after-hours trading following the announcement.</p>\n<p>Nio’s move follows similar offerings by three other public EV companies in roughly the past week. Tesla Inc.TSLA,+3.74%announced a $5 billion at-the-market offering Tuesday morning, andcompleted that stock sale within roughly 24 hours, according to a filing with the Securities and Exchange Commission. It was the second $5 billion stock offering from Elon Musk’s U.S. electric-car manufacturer in three months, and third stock offering of the year.</p>\n<p>Tesla followed two of its other Chinese rivals in selling fresh shares. XPeng Inc.XPEV,+0.34%disclosed the planned sale of 40 million new shares on Monday, after Li Auto Inc.LI,+1.44%announced last Wednesday thatit was selling 47 million new shares. Both stocks struggled in the wake of those announcements.</p>\n<p>Despite the momentary dips amid stock offerings, EV stocks are enjoying a 2020 stock surge. So far this year, Tesla stock has gained roughly 650%, Nio shares have increased more than 1,000%, Xpeng shares have gained more than 111%, and Li Auto stock is up more than 97%. The S&amp;P 500 indexSPX,-0.13%has gained 13% so far this year, and plans to welcome Tesla into its ranks later this month.</p>\n<p>Nio’s share sale will be led by Morgan Stanley and China International Capital Corporation Hong Kong Securities Ltd.</p>","source":"lsy1603348471595","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Nio joins Tesla and other rivals in rush to offer more shares in electric-vehicle companies</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNio joins Tesla and other rivals in rush to offer more shares in electric-vehicle companies\n</h2>\n\n<h4 class=\"meta\">\n\n\n2020-12-11 11:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.marketwatch.com/story/nio-joins-tesla-and-other-rivals-in-rush-to-offer-more-shares-in-electric-vehicle-companies-11607641044?mod=home-page><strong>marketwatch</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Chinese electric-car company plans to sell up to 69 million fresh shares in U.S., after competitors Tesla, XPeng and Li Auto announced stock-sale plans.\nElectric-car companies may be selling more ...</p>\n\n<a href=\"https://www.marketwatch.com/story/nio-joins-tesla-and-other-rivals-in-rush-to-offer-more-shares-in-electric-vehicle-companies-11607641044?mod=home-page\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NIO":"蔚来","TSLA":"特斯拉"},"source_url":"https://www.marketwatch.com/story/nio-joins-tesla-and-other-rivals-in-rush-to-offer-more-shares-in-electric-vehicle-companies-11607641044?mod=home-page","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1165742728","content_text":"Chinese electric-car company plans to sell up to 69 million fresh shares in U.S., after competitors Tesla, XPeng and Li Auto announced stock-sale plans.\nElectric-car companies may be selling more shares than cars at the end of 2020.\nAmid an explosion in stock prices of electric-vehicle manufacturers, Chinese EV company Nio Inc.NIO,+2.75%announced Thursday afternoon that it plans to sell at least 60 million fresh American depositary shares, with an additional 9 million shares available to underwriters. Nio stock dropped more than 4% in after-hours trading following the announcement.\nNio’s move follows similar offerings by three other public EV companies in roughly the past week. Tesla Inc.TSLA,+3.74%announced a $5 billion at-the-market offering Tuesday morning, andcompleted that stock sale within roughly 24 hours, according to a filing with the Securities and Exchange Commission. It was the second $5 billion stock offering from Elon Musk’s U.S. electric-car manufacturer in three months, and third stock offering of the year.\nTesla followed two of its other Chinese rivals in selling fresh shares. XPeng Inc.XPEV,+0.34%disclosed the planned sale of 40 million new shares on Monday, after Li Auto Inc.LI,+1.44%announced last Wednesday thatit was selling 47 million new shares. Both stocks struggled in the wake of those announcements.\nDespite the momentary dips amid stock offerings, EV stocks are enjoying a 2020 stock surge. So far this year, Tesla stock has gained roughly 650%, Nio shares have increased more than 1,000%, Xpeng shares have gained more than 111%, and Li Auto stock is up more than 97%. The S&P 500 indexSPX,-0.13%has gained 13% so far this year, and plans to welcome Tesla into its ranks later this month.\nNio’s share sale will be led by Morgan Stanley and China International Capital Corporation Hong Kong Securities Ltd.","news_type":1,"symbols_score_info":{"TSLA":0.9,"NIO":0.9}},"isVote":1,"tweetType":1,"viewCount":1627,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":392265506,"gmtCreate":1607453940405,"gmtModify":1704970339698,"author":{"id":"3570084474850154","authorId":"3570084474850154","name":"kelvinnkq","avatar":"https://static.tigerbbs.com/a0288c00e3e6ae4f8970e539301a0694","crmLevel":11,"crmLevelSwitch":1,"followedFlag":false,"authorIdStr":"3570084474850154","idStr":"3570084474850154"},"themes":[],"htmlText":".","listText":".","text":".","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/392265506","repostId":"2090759310","repostType":2,"repost":{"id":"2090759310","kind":"highlight","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1607453849,"share":"https://ttm.financial/m/news/2090759310?lang=&edition=fundamental","pubTime":"2020-12-09 02:57","market":"us","language":"en","title":"LIVE MARKETS-FANG Index: Still getting its teeth \"cleaned\"","url":"https://stock-news.laohu8.com/highlight/detail?id=2090759310","media":"Reuters","summary":"* Major U.S. averages in positive territory; small caps outperform   * S&P 500, Nasdaq hit new highs","content":"<html><body><p>* Major U.S. averages in positive territory; small caps outperform</p><p>   * S&amp;P 500, Nasdaq hit new highs</p><p>   * Energy leads major S&amp;P sector gainers; cons disc weakest group</p><p>   * Dollar, gold higher, crude slips</p><p>   * U.S. 10-year Treasury yield ~0.91%</p><p>    Dec 8 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com </p><p>   FANG INDEX: STILL GETTING ITS TEETH \"CLEANED\" (1345 EST/1845 GMT)</p><p>   The NYSE FANG+TM Index    has long been a market leader. Indeed, this basket of high-growth tech stocks has captured the market's fancy for some time.  </p><p>   However, with 2020 nearing an end, and even with a 90% year-to-date rise, the FANG index has been cowering before another group, and that's clean energy.  </p><p>   The Invesco WilderHill Clean Energy ETF   , whose top holdings include such stocks as NIO   , JinkoSolar    and <a href=\"https://laohu8.com/S/SPWR\">SunPower</a>    is up more than 170% this year, and currently on track for its biggest yearly percentage rise in its full-year history going back to 2006.  </p><p>   Meanwhile, after essentially forming a double top from 2018-2020, the NYFANG/WilderHill Clean Energy Index    ratio collapsed to a 4-1/2 year low in late November. (Click on chart below)</p><p>   Despite a modest bounce off a support line drawn from a mid-2018 low, the ratio has turned down again. If it continues to decline below the November trough at 29.04, the ratio could be on track to meet the double-top pattern projection in the 21.00 area. This would suggest greater NYFANG underperformance vs ECO.</p><p>   The ratio has work to do to turn its trend back up, but a push above the early December high at 32.44 can clear the way to challenge the sharply descending 50-day moving average. A reversal above the late-October high, at 42.11, would end the pattern of declining peaks and troughs from the April 2020 top.</p><p>   (Terence Gabriel)</p><p>   *****</p><p>   PANDEMICS AND PARADIGMS: COVID'S LASTING EFFECTS ON BEHAVIOR AND INDUSTRY (1241 EST/1741 GMT)</p><p>   Just as effects of COVID-19 can linger in recovered patients, some analysts see the pandemic driving behavioral shifts that will linger after the pandemic ends, and impact global industry.    </p><p>   A research note from Oxford Economics identifies these changes in behavior and explores how they might prompt shifts in the pre-COVID paradigm.</p><p>   \"Some behavioral shifts will leave scars in certain sectors, while others will open up opportunities in the year ahead,\" writes Stephen Foreman, lead industry economist at OE.</p><p>   First, social distancing has sent digitalization into overdrive as companies and individuals adjust how they work, spend and interact, according to the note.</p><p>   \"We expect this trend to persist into next year, supporting growth prospects in sectors such as healthcare, financial services, and e-commerce,\" Foreman adds.</p><p>   But he doesn't think all boats will rise with the digitalization tide, with the new work-from-home normal likely pressuring construction activity and commercial real estate.    </p><p>   Next, globalization is likely to be dampened by the pandemic, as companies seek to bring production closer to home. </p><p>   \"But such shifts take time, so are unlikely to be widely seen in 2021,\" Foreman says. \"And the backlash isn't universal – the appetite for globalization is strong in Asia Pacific.\" </p><p>   However, the travel industry is <a href=\"https://laohu8.com/S/AONE\">one</a> sector that could see lasting effects of de-globalization. Oxford Economics sees domestic travel driving the recovery of commercial airlines, for example, with international demand as a share of total demand remaining lower next year and into the medium term.</p><p>   Finally, Foreman believes the clean energy industry will be jump-started in COVID's wake.</p><p>   \"We’ve seen a clear desire to put green investment and tackling climate change at the forefront of recovery spending,\" Foreman says, citing allocations of the EU's recovery fund and the likelihood of president-elect Joe Biden reversing President Trump's executive actions on energy policy.</p><p>   Electric vehicles will \"break into the mainstream\" in 2021, with market share in Europe and China reaching <a href=\"https://laohu8.com/S/AONE.U\">one</a>-third of the total, the note says.</p><p>   While this shift could benefit some chemical firms due to increased demand for materials used in EV construction, it could also have a negative impact on machinery makers, as battery-driven cars have fewer moving parts, as Foreman observes.          </p><p>   (Stephen Culp)</p><p>   *****</p><p>   SHAKESPEARE'S 2020 WINTER'S TALE ENDS WELL FOR EUROPE (1203 EST/1703 GMT) </p><p>   A man named William Shakespeare being among the first batch of people being vaccinated in the UK against COVID-19 was definitely the feel-good story of the day in Europe. </p><p>   According to Wikipedia, (the author of these lines confesses never having read that play) Shakespeare's Winter's Tale has some kind of bitter-sweet ending which is kind of what happened to the STOXX 600, which closed up 0.2% but with ugly pandemic and Brexit worries lingering in the background.</p><p>   All in all it was a pretty mixed session with Paris and Milan losing 0.2% and London and Frankfurt making gains below 0.1%.        </p><p>   The lack of conviction is understandable given there's still no visibility on whether the EU and Britain will find a compromise to avoid a messy and painful start to 2021 if no post-Brexit trade deal is agreed. </p><p>   And while the start of the vaccine roll-out in the UK is great news, the pandemic is still a threat for the coming months and is visibly weighing on Wall Street. </p><p>   It must also be noted that the news that AstraZeneca and Oxford University have more work to do to confirm whether their COVID-19 vaccine can be 90% effective was also disappointing.</p><p>   Some reading to catch up with European news:</p><p>   In England, William Shakespeare receives a COVID-19 vaccine</p><p>   In COVID-19 milestone for West, Britain starts mass vaccination   </p><p>   As Brexit deadline looms, Johnson says Britain may abandon trade talks   </p><p>   Testing times: More work needed on Astra/Oxford vaccine trials  </p><p>   (Julien Ponthus) </p><p>   *****  </p><p>   CAN THE RALLY KEEP GOING WITHOUT TECH? (1106 EST/1606 GMT)</p><p>   While the S&amp;P 500    has made several record highs since early  September - four intraday record highs and seven record closes to be precise - Bespoke Investment Group points out that it reached these records despite the fact that the benchmark's heavyweight technology sector index    has not had a 52 week high in 50 trading sessions.  </p><p>   \"Given that it's the largest sector in the market by a wide margin, there have been relatively few instances in the past where the S&amp;P 500 has made a new 52-week high and the Technology sector had yet to arrive at the party,\" said Bespoke.</p><p>   According to Bespoke there have only been eleven other instances since 1990 where the S&amp;P 500 made a 52-week high while tech was at least 50 trading days removed from its last high.</p><p>  So can the market continue to rally without more tech sector records? Looking at history, Bespoke says the answer is yes. </p><p>   In the past when the S&amp;P has hit record highs without tech, over the following one and three months, the benchmark's average and median returns, as well as its frequency of positive returns, outstripped comparable returns for the Technology sector, according to the research. </p><p>   And in those individual periods technology outperformed the broader market only four out of those 11 instances, Bespoke said.    </p><p>   The last time the S&amp;P tech sector hit a record high was on Sept. 2 and its intraday high so far on Tuesday was roughly 0.8% below that record.</p><p>   (Sinéad Carew)</p><p>    *****</p><p>   SMALL BUSINESS OWNERS: STILL SMILING, BUT WITH WORRY LINES (1004 EST/1504 GMT)</p><p>   Small business sentiment in the U.S. remained essentially optimistic last month, but uncertainties surrounding the upcoming Georgia run-off elections - which will determine which party controls the Senate - and new restrictions to curb a spiking pandemic have slightly dulled the shine on their shoes.</p><p>   The National Federation of Independent Business (NFIB) Optimism Index    dipped nearly three points in November to a reading of 101.4, the largest one-month drop since the beginning of the recovery. Still, it remains above the 47-year average of 98.</p><p>   Six of the ten subcomponents declined, while four increased. Expectations of improving business conditions over the next six months slid 19 points to a net positive 8%, the lowest level since April. The Uncertainty index abated, but remains at \"historically high\" levels, according to NFIB.</p><p>   Survey participants said finding qualified workers was their top business problem, exceeding taxes, regulations and poor sales.</p><p>   Depressed inventories, a theme repeated in GDP and PMI data, remain an overhang. Although a majority of owners described their inventories as \"too low\" plans to invest in more inventory accumulation collapsed from record levels.</p><p>   \"The recovery will remain uneven as long as we see state and local mandates that target business conditions and disproportionately affect small businesses,\" writes Bill Dunkelberg, chief economist at NFIB.</p><p>   Oren Klachkin, lead U.S. economist at Oxford Economics, agrees.</p><p>   \"Small businesses will face the greatest risk of failure as the recovery slows, especially if lawmakers don’t offer more aid,\" Klachkin says.</p><p>    Separately, the Labor Department released revised data for third-quarter labor costs and productivity.</p><p>   Labor costs    fell 6.6% in the quarter, shallower than the 8.9% previously reported, while productivity - or output per hour    - rose by 4.6%, slower than the originally-stated 4.9% increase.  </p><p>   \"The data have been especially volatile quarter-to-quarter reflecting the impact of Covid-19 on output, hours and compensation,\" says Rubeela Farooqi, chief U.S. economist at High Frequency Economics. \"The underlying trend in productivity will likely moderate from the current pace over coming quarters.\"</p><p>   Caution kept buyers at bay in early trading.</p><p>   All three major U.S. stock indexes are red, with losses in market-leading mega-cap tech and tech-adjacent shares putting the Nasdaq on course to snap its three-day record closing streak.</p><p>   (Stephen Culp)</p><p>   *****</p><p>   PRODUCTIVITY BOUNCE ON THE HORIZON (0913 EST/1413 GMT)</p><p>   Whether underpriced value is finally overtaking growth stocks remains a question on Wall Street, but as the go-go era tapers off, several years of stronger productivity could arrive to bolster equities, tap down inflation and hamper bond returns.</p><p>   The observation comes from Jim Paulsen, chief investment strategist at the Leuthold Group in Minneapolis, who says while an imperfect relationship, more robust productivity often has followed periods of growth-style dominance after World War II.</p><p>   But when value beats growth returns, weak productivity too often rules, Paulsen said in a note to investors.</p><p>   It takes time before a new product's innovative attributes are fully communicated, disseminated, understood and implemented into business and households, Paulsen said. That's why there is a multi-year lag between a growth cycle and rising productivity.</p><p>   Since 1947 as productivity rose, average inflation weakened and average bond returns declined. The usual negative linkage between inflation and bond returns is altered by productivity.</p><p>   Overall economic growth tends to be healthy, forcing yields higher and bond returns lower. If the U.S. economy is poised for a period of superior productivity, investors should prepare for a challenging bond market, even with modest inflation, but a  rising equity market, he said.</p><p>   The future power of U.S. core capital goods orders after they recently surged to an all-time record during a pandemic should not be underestimated, Paulsen said.</p><p>   (Herbert Lash)</p><p>   *****</p><p>   S&amp;P 500: FORK IN THE SKY? (0845 EST/1345 GMT)</p><p>   As the S&amp;P 500 index    attempts to forthrightly thrust above a significant resistance barrier  , the Northern Hemisphere's winter solstice is just over the horizon. Thus, it may shortly become clear whether the benchmark index is on the verge of a moon-shot to fresh records, or if the solstice's orb of influence will coincide with another major reversal. </p><p>   Proponents of Gann Theory, or methods of technical analysis developed by trader W.D. Gann, may look for either acceleration of the prevailing trend, or a reversal, around the summer and winter solstices, as well as the fall and spring equinoxes.</p><p>   Looking back over the past 2 years or so there has been interesting market action around these events. So far in 2020, these dates have all coincided with then end of periods of significant decline. (Click on chart below)</p><p>   The 2020 spring equinox took place on Thursday, March 19, at 11:49 PM EDT. Two trading days later, the S&amp;P 500 put in a surprise bottom that ended the more than 30% February/March bear market.</p><p>   The summer solstice occurred on Saturday, June 20, at 5:43 PM EDT. Earlier that week, the SPX abruptly ended what was a more than 8% one-week slide.</p><p>   The fall equinox took place on Tuesday, September 22 at 09:30 AM EDT. Just one day later, the SPX ended what was essentially a 10% correction from its early September high.</p><p>   The coming solstice happens at 5:02 AM EST on December 21st. It now remains to be seen if around this date, the SPX will accelerate higher, or succumb to gravity.</p><p>   Meanwhile, amid the pitch and yaw, there are signs of an overheated market  , permeated by great complacency</p><p> . That said, advance/decline lines are still providing tailwinds.  </p><p>   (Terence Gabriel)</p><p>   *****</p><p>   FOR TUESDAY'S LIVE MARKETS' POSTS PRIOR TO 0845 EST/1345 GMT - CLICK HERE:  </p><p>    &lt;^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ SPX12082020F     NFIB     Productivity and labor costs     FANGECO12082020    </p><p>   ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^&gt;</p><p>(Terence Gabriel is a Reuters market analyst. The views expressed are his own)</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LIVE MARKETS-FANG Index: Still getting its teeth \"cleaned\"</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLIVE MARKETS-FANG Index: Still getting its teeth \"cleaned\"\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2020-12-09 02:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>* Major U.S. averages in positive territory; small caps outperform</p><p>   * S&amp;P 500, Nasdaq hit new highs</p><p>   * Energy leads major S&amp;P sector gainers; cons disc weakest group</p><p>   * Dollar, gold higher, crude slips</p><p>   * U.S. 10-year Treasury yield ~0.91%</p><p>    Dec 8 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com </p><p>   FANG INDEX: STILL GETTING ITS TEETH \"CLEANED\" (1345 EST/1845 GMT)</p><p>   The NYSE FANG+TM Index    has long been a market leader. Indeed, this basket of high-growth tech stocks has captured the market's fancy for some time.  </p><p>   However, with 2020 nearing an end, and even with a 90% year-to-date rise, the FANG index has been cowering before another group, and that's clean energy.  </p><p>   The Invesco WilderHill Clean Energy ETF   , whose top holdings include such stocks as NIO   , JinkoSolar    and <a href=\"https://laohu8.com/S/SPWR\">SunPower</a>    is up more than 170% this year, and currently on track for its biggest yearly percentage rise in its full-year history going back to 2006.  </p><p>   Meanwhile, after essentially forming a double top from 2018-2020, the NYFANG/WilderHill Clean Energy Index    ratio collapsed to a 4-1/2 year low in late November. (Click on chart below)</p><p>   Despite a modest bounce off a support line drawn from a mid-2018 low, the ratio has turned down again. If it continues to decline below the November trough at 29.04, the ratio could be on track to meet the double-top pattern projection in the 21.00 area. This would suggest greater NYFANG underperformance vs ECO.</p><p>   The ratio has work to do to turn its trend back up, but a push above the early December high at 32.44 can clear the way to challenge the sharply descending 50-day moving average. A reversal above the late-October high, at 42.11, would end the pattern of declining peaks and troughs from the April 2020 top.</p><p>   (Terence Gabriel)</p><p>   *****</p><p>   PANDEMICS AND PARADIGMS: COVID'S LASTING EFFECTS ON BEHAVIOR AND INDUSTRY (1241 EST/1741 GMT)</p><p>   Just as effects of COVID-19 can linger in recovered patients, some analysts see the pandemic driving behavioral shifts that will linger after the pandemic ends, and impact global industry.    </p><p>   A research note from Oxford Economics identifies these changes in behavior and explores how they might prompt shifts in the pre-COVID paradigm.</p><p>   \"Some behavioral shifts will leave scars in certain sectors, while others will open up opportunities in the year ahead,\" writes Stephen Foreman, lead industry economist at OE.</p><p>   First, social distancing has sent digitalization into overdrive as companies and individuals adjust how they work, spend and interact, according to the note.</p><p>   \"We expect this trend to persist into next year, supporting growth prospects in sectors such as healthcare, financial services, and e-commerce,\" Foreman adds.</p><p>   But he doesn't think all boats will rise with the digitalization tide, with the new work-from-home normal likely pressuring construction activity and commercial real estate.    </p><p>   Next, globalization is likely to be dampened by the pandemic, as companies seek to bring production closer to home. </p><p>   \"But such shifts take time, so are unlikely to be widely seen in 2021,\" Foreman says. \"And the backlash isn't universal – the appetite for globalization is strong in Asia Pacific.\" </p><p>   However, the travel industry is <a href=\"https://laohu8.com/S/AONE\">one</a> sector that could see lasting effects of de-globalization. Oxford Economics sees domestic travel driving the recovery of commercial airlines, for example, with international demand as a share of total demand remaining lower next year and into the medium term.</p><p>   Finally, Foreman believes the clean energy industry will be jump-started in COVID's wake.</p><p>   \"We’ve seen a clear desire to put green investment and tackling climate change at the forefront of recovery spending,\" Foreman says, citing allocations of the EU's recovery fund and the likelihood of president-elect Joe Biden reversing President Trump's executive actions on energy policy.</p><p>   Electric vehicles will \"break into the mainstream\" in 2021, with market share in Europe and China reaching <a href=\"https://laohu8.com/S/AONE.U\">one</a>-third of the total, the note says.</p><p>   While this shift could benefit some chemical firms due to increased demand for materials used in EV construction, it could also have a negative impact on machinery makers, as battery-driven cars have fewer moving parts, as Foreman observes.          </p><p>   (Stephen Culp)</p><p>   *****</p><p>   SHAKESPEARE'S 2020 WINTER'S TALE ENDS WELL FOR EUROPE (1203 EST/1703 GMT) </p><p>   A man named William Shakespeare being among the first batch of people being vaccinated in the UK against COVID-19 was definitely the feel-good story of the day in Europe. </p><p>   According to Wikipedia, (the author of these lines confesses never having read that play) Shakespeare's Winter's Tale has some kind of bitter-sweet ending which is kind of what happened to the STOXX 600, which closed up 0.2% but with ugly pandemic and Brexit worries lingering in the background.</p><p>   All in all it was a pretty mixed session with Paris and Milan losing 0.2% and London and Frankfurt making gains below 0.1%.        </p><p>   The lack of conviction is understandable given there's still no visibility on whether the EU and Britain will find a compromise to avoid a messy and painful start to 2021 if no post-Brexit trade deal is agreed. </p><p>   And while the start of the vaccine roll-out in the UK is great news, the pandemic is still a threat for the coming months and is visibly weighing on Wall Street. </p><p>   It must also be noted that the news that AstraZeneca and Oxford University have more work to do to confirm whether their COVID-19 vaccine can be 90% effective was also disappointing.</p><p>   Some reading to catch up with European news:</p><p>   In England, William Shakespeare receives a COVID-19 vaccine</p><p>   In COVID-19 milestone for West, Britain starts mass vaccination   </p><p>   As Brexit deadline looms, Johnson says Britain may abandon trade talks   </p><p>   Testing times: More work needed on Astra/Oxford vaccine trials  </p><p>   (Julien Ponthus) </p><p>   *****  </p><p>   CAN THE RALLY KEEP GOING WITHOUT TECH? (1106 EST/1606 GMT)</p><p>   While the S&amp;P 500    has made several record highs since early  September - four intraday record highs and seven record closes to be precise - Bespoke Investment Group points out that it reached these records despite the fact that the benchmark's heavyweight technology sector index    has not had a 52 week high in 50 trading sessions.  </p><p>   \"Given that it's the largest sector in the market by a wide margin, there have been relatively few instances in the past where the S&amp;P 500 has made a new 52-week high and the Technology sector had yet to arrive at the party,\" said Bespoke.</p><p>   According to Bespoke there have only been eleven other instances since 1990 where the S&amp;P 500 made a 52-week high while tech was at least 50 trading days removed from its last high.</p><p>  So can the market continue to rally without more tech sector records? Looking at history, Bespoke says the answer is yes. </p><p>   In the past when the S&amp;P has hit record highs without tech, over the following one and three months, the benchmark's average and median returns, as well as its frequency of positive returns, outstripped comparable returns for the Technology sector, according to the research. </p><p>   And in those individual periods technology outperformed the broader market only four out of those 11 instances, Bespoke said.    </p><p>   The last time the S&amp;P tech sector hit a record high was on Sept. 2 and its intraday high so far on Tuesday was roughly 0.8% below that record.</p><p>   (Sinéad Carew)</p><p>    *****</p><p>   SMALL BUSINESS OWNERS: STILL SMILING, BUT WITH WORRY LINES (1004 EST/1504 GMT)</p><p>   Small business sentiment in the U.S. remained essentially optimistic last month, but uncertainties surrounding the upcoming Georgia run-off elections - which will determine which party controls the Senate - and new restrictions to curb a spiking pandemic have slightly dulled the shine on their shoes.</p><p>   The National Federation of Independent Business (NFIB) Optimism Index    dipped nearly three points in November to a reading of 101.4, the largest one-month drop since the beginning of the recovery. Still, it remains above the 47-year average of 98.</p><p>   Six of the ten subcomponents declined, while four increased. Expectations of improving business conditions over the next six months slid 19 points to a net positive 8%, the lowest level since April. The Uncertainty index abated, but remains at \"historically high\" levels, according to NFIB.</p><p>   Survey participants said finding qualified workers was their top business problem, exceeding taxes, regulations and poor sales.</p><p>   Depressed inventories, a theme repeated in GDP and PMI data, remain an overhang. Although a majority of owners described their inventories as \"too low\" plans to invest in more inventory accumulation collapsed from record levels.</p><p>   \"The recovery will remain uneven as long as we see state and local mandates that target business conditions and disproportionately affect small businesses,\" writes Bill Dunkelberg, chief economist at NFIB.</p><p>   Oren Klachkin, lead U.S. economist at Oxford Economics, agrees.</p><p>   \"Small businesses will face the greatest risk of failure as the recovery slows, especially if lawmakers don’t offer more aid,\" Klachkin says.</p><p>    Separately, the Labor Department released revised data for third-quarter labor costs and productivity.</p><p>   Labor costs    fell 6.6% in the quarter, shallower than the 8.9% previously reported, while productivity - or output per hour    - rose by 4.6%, slower than the originally-stated 4.9% increase.  </p><p>   \"The data have been especially volatile quarter-to-quarter reflecting the impact of Covid-19 on output, hours and compensation,\" says Rubeela Farooqi, chief U.S. economist at High Frequency Economics. \"The underlying trend in productivity will likely moderate from the current pace over coming quarters.\"</p><p>   Caution kept buyers at bay in early trading.</p><p>   All three major U.S. stock indexes are red, with losses in market-leading mega-cap tech and tech-adjacent shares putting the Nasdaq on course to snap its three-day record closing streak.</p><p>   (Stephen Culp)</p><p>   *****</p><p>   PRODUCTIVITY BOUNCE ON THE HORIZON (0913 EST/1413 GMT)</p><p>   Whether underpriced value is finally overtaking growth stocks remains a question on Wall Street, but as the go-go era tapers off, several years of stronger productivity could arrive to bolster equities, tap down inflation and hamper bond returns.</p><p>   The observation comes from Jim Paulsen, chief investment strategist at the Leuthold Group in Minneapolis, who says while an imperfect relationship, more robust productivity often has followed periods of growth-style dominance after World War II.</p><p>   But when value beats growth returns, weak productivity too often rules, Paulsen said in a note to investors.</p><p>   It takes time before a new product's innovative attributes are fully communicated, disseminated, understood and implemented into business and households, Paulsen said. That's why there is a multi-year lag between a growth cycle and rising productivity.</p><p>   Since 1947 as productivity rose, average inflation weakened and average bond returns declined. The usual negative linkage between inflation and bond returns is altered by productivity.</p><p>   Overall economic growth tends to be healthy, forcing yields higher and bond returns lower. If the U.S. economy is poised for a period of superior productivity, investors should prepare for a challenging bond market, even with modest inflation, but a  rising equity market, he said.</p><p>   The future power of U.S. core capital goods orders after they recently surged to an all-time record during a pandemic should not be underestimated, Paulsen said.</p><p>   (Herbert Lash)</p><p>   *****</p><p>   S&amp;P 500: FORK IN THE SKY? (0845 EST/1345 GMT)</p><p>   As the S&amp;P 500 index    attempts to forthrightly thrust above a significant resistance barrier  , the Northern Hemisphere's winter solstice is just over the horizon. Thus, it may shortly become clear whether the benchmark index is on the verge of a moon-shot to fresh records, or if the solstice's orb of influence will coincide with another major reversal. </p><p>   Proponents of Gann Theory, or methods of technical analysis developed by trader W.D. Gann, may look for either acceleration of the prevailing trend, or a reversal, around the summer and winter solstices, as well as the fall and spring equinoxes.</p><p>   Looking back over the past 2 years or so there has been interesting market action around these events. So far in 2020, these dates have all coincided with then end of periods of significant decline. (Click on chart below)</p><p>   The 2020 spring equinox took place on Thursday, March 19, at 11:49 PM EDT. Two trading days later, the S&amp;P 500 put in a surprise bottom that ended the more than 30% February/March bear market.</p><p>   The summer solstice occurred on Saturday, June 20, at 5:43 PM EDT. Earlier that week, the SPX abruptly ended what was a more than 8% one-week slide.</p><p>   The fall equinox took place on Tuesday, September 22 at 09:30 AM EDT. Just one day later, the SPX ended what was essentially a 10% correction from its early September high.</p><p>   The coming solstice happens at 5:02 AM EST on December 21st. It now remains to be seen if around this date, the SPX will accelerate higher, or succumb to gravity.</p><p>   Meanwhile, amid the pitch and yaw, there are signs of an overheated market  , permeated by great complacency</p><p> . That said, advance/decline lines are still providing tailwinds.  </p><p>   (Terence Gabriel)</p><p>   *****</p><p>   FOR TUESDAY'S LIVE MARKETS' POSTS PRIOR TO 0845 EST/1345 GMT - CLICK HERE:  </p><p>    &lt;^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ SPX12082020F     NFIB     Productivity and labor costs     FANGECO12082020    </p><p>   ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^&gt;</p><p>(Terence Gabriel is a Reuters market analyst. The views expressed are his own)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"SCO":"二倍做空彭博原油指数ETF","QNETCN":"纳斯达克中美互联网老虎指数","09988":"阿里巴巴-W","DDM":"2倍做多道指ETF-ProShares","DXD":"两倍做空道琼30指数ETF-ProShares","USO":"美国原油ETF","TSLA":"特斯拉",".DJI":"道琼斯","SPWR":"Sunpower Inc.","NVDA":"英伟达","QID":"两倍做空纳斯达克指数ETF-ProShares","DOG":"道指ETF-ProShares做空",".IXIC":"NASDAQ Composite","PSQ":"做空纳斯达克100指数ETF-ProShares",".SPX":"S&P 500 Index","09086":"华夏纳指-U","UDOW":"三倍做多道指30ETF-ProShares","GOOGL":"谷歌A","FB":"ProShares S&P 500 Dynamic Buffer ETF","SDOW":"三倍做空道指30ETF-ProShares","AAPL":"苹果","03086":"华夏纳指","DWT":"三倍做空原油ETN","UCO":"二倍做多彭博原油ETF","NFLX":"奈飞","NIO":"蔚来","DUG":"二倍做空石油与天然气ETF(ProShares)","QQQ":"纳指100ETF","BIDU":"百度","JKS":"晶科能源","SQQQ":"纳指三倍做空ETF","DJX":"1/100道琼斯","TWTR":"Twitter","DDG":"ProShares做空石油与天然气ETF","TQQQ":"纳指三倍做多ETF","QLD":"2倍做多纳斯达克100指数ETF-ProShares","AMZN":"亚马逊"},"source_url":"http://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2090759310","content_text":"* Major U.S. averages in positive territory; small caps outperform   * S&P 500, Nasdaq hit new highs   * Energy leads major S&P sector gainers; cons disc weakest group   * Dollar, gold higher, crude slips   * U.S. 10-year Treasury yield ~0.91%    Dec 8 - Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com    FANG INDEX: STILL GETTING ITS TEETH \"CLEANED\" (1345 EST/1845 GMT)   The NYSE FANG+TM Index    has long been a market leader. Indeed, this basket of high-growth tech stocks has captured the market's fancy for some time.     However, with 2020 nearing an end, and even with a 90% year-to-date rise, the FANG index has been cowering before another group, and that's clean energy.     The Invesco WilderHill Clean Energy ETF   , whose top holdings include such stocks as NIO   , JinkoSolar    and SunPower    is up more than 170% this year, and currently on track for its biggest yearly percentage rise in its full-year history going back to 2006.     Meanwhile, after essentially forming a double top from 2018-2020, the NYFANG/WilderHill Clean Energy Index    ratio collapsed to a 4-1/2 year low in late November. (Click on chart below)   Despite a modest bounce off a support line drawn from a mid-2018 low, the ratio has turned down again. If it continues to decline below the November trough at 29.04, the ratio could be on track to meet the double-top pattern projection in the 21.00 area. This would suggest greater NYFANG underperformance vs ECO.   The ratio has work to do to turn its trend back up, but a push above the early December high at 32.44 can clear the way to challenge the sharply descending 50-day moving average. A reversal above the late-October high, at 42.11, would end the pattern of declining peaks and troughs from the April 2020 top.   (Terence Gabriel)   *****   PANDEMICS AND PARADIGMS: COVID'S LASTING EFFECTS ON BEHAVIOR AND INDUSTRY (1241 EST/1741 GMT)   Just as effects of COVID-19 can linger in recovered patients, some analysts see the pandemic driving behavioral shifts that will linger after the pandemic ends, and impact global industry.       A research note from Oxford Economics identifies these changes in behavior and explores how they might prompt shifts in the pre-COVID paradigm.   \"Some behavioral shifts will leave scars in certain sectors, while others will open up opportunities in the year ahead,\" writes Stephen Foreman, lead industry economist at OE.   First, social distancing has sent digitalization into overdrive as companies and individuals adjust how they work, spend and interact, according to the note.   \"We expect this trend to persist into next year, supporting growth prospects in sectors such as healthcare, financial services, and e-commerce,\" Foreman adds.   But he doesn't think all boats will rise with the digitalization tide, with the new work-from-home normal likely pressuring construction activity and commercial real estate.       Next, globalization is likely to be dampened by the pandemic, as companies seek to bring production closer to home.    \"But such shifts take time, so are unlikely to be widely seen in 2021,\" Foreman says. \"And the backlash isn't universal – the appetite for globalization is strong in Asia Pacific.\"    However, the travel industry is one sector that could see lasting effects of de-globalization. Oxford Economics sees domestic travel driving the recovery of commercial airlines, for example, with international demand as a share of total demand remaining lower next year and into the medium term.   Finally, Foreman believes the clean energy industry will be jump-started in COVID's wake.   \"We’ve seen a clear desire to put green investment and tackling climate change at the forefront of recovery spending,\" Foreman says, citing allocations of the EU's recovery fund and the likelihood of president-elect Joe Biden reversing President Trump's executive actions on energy policy.   Electric vehicles will \"break into the mainstream\" in 2021, with market share in Europe and China reaching one-third of the total, the note says.   While this shift could benefit some chemical firms due to increased demand for materials used in EV construction, it could also have a negative impact on machinery makers, as battery-driven cars have fewer moving parts, as Foreman observes.             (Stephen Culp)   *****   SHAKESPEARE'S 2020 WINTER'S TALE ENDS WELL FOR EUROPE (1203 EST/1703 GMT)    A man named William Shakespeare being among the first batch of people being vaccinated in the UK against COVID-19 was definitely the feel-good story of the day in Europe.    According to Wikipedia, (the author of these lines confesses never having read that play) Shakespeare's Winter's Tale has some kind of bitter-sweet ending which is kind of what happened to the STOXX 600, which closed up 0.2% but with ugly pandemic and Brexit worries lingering in the background.   All in all it was a pretty mixed session with Paris and Milan losing 0.2% and London and Frankfurt making gains below 0.1%.           The lack of conviction is understandable given there's still no visibility on whether the EU and Britain will find a compromise to avoid a messy and painful start to 2021 if no post-Brexit trade deal is agreed.    And while the start of the vaccine roll-out in the UK is great news, the pandemic is still a threat for the coming months and is visibly weighing on Wall Street.    It must also be noted that the news that AstraZeneca and Oxford University have more work to do to confirm whether their COVID-19 vaccine can be 90% effective was also disappointing.   Some reading to catch up with European news:   In England, William Shakespeare receives a COVID-19 vaccine   In COVID-19 milestone for West, Britain starts mass vaccination      As Brexit deadline looms, Johnson says Britain may abandon trade talks      Testing times: More work needed on Astra/Oxford vaccine trials     (Julien Ponthus)    *****     CAN THE RALLY KEEP GOING WITHOUT TECH? (1106 EST/1606 GMT)   While the S&P 500    has made several record highs since early  September - four intraday record highs and seven record closes to be precise - Bespoke Investment Group points out that it reached these records despite the fact that the benchmark's heavyweight technology sector index    has not had a 52 week high in 50 trading sessions.     \"Given that it's the largest sector in the market by a wide margin, there have been relatively few instances in the past where the S&P 500 has made a new 52-week high and the Technology sector had yet to arrive at the party,\" said Bespoke.   According to Bespoke there have only been eleven other instances since 1990 where the S&P 500 made a 52-week high while tech was at least 50 trading days removed from its last high.  So can the market continue to rally without more tech sector records? Looking at history, Bespoke says the answer is yes.    In the past when the S&P has hit record highs without tech, over the following one and three months, the benchmark's average and median returns, as well as its frequency of positive returns, outstripped comparable returns for the Technology sector, according to the research.    And in those individual periods technology outperformed the broader market only four out of those 11 instances, Bespoke said.       The last time the S&P tech sector hit a record high was on Sept. 2 and its intraday high so far on Tuesday was roughly 0.8% below that record.   (Sinéad Carew)    *****   SMALL BUSINESS OWNERS: STILL SMILING, BUT WITH WORRY LINES (1004 EST/1504 GMT)   Small business sentiment in the U.S. remained essentially optimistic last month, but uncertainties surrounding the upcoming Georgia run-off elections - which will determine which party controls the Senate - and new restrictions to curb a spiking pandemic have slightly dulled the shine on their shoes.   The National Federation of Independent Business (NFIB) Optimism Index    dipped nearly three points in November to a reading of 101.4, the largest one-month drop since the beginning of the recovery. Still, it remains above the 47-year average of 98.   Six of the ten subcomponents declined, while four increased. Expectations of improving business conditions over the next six months slid 19 points to a net positive 8%, the lowest level since April. The Uncertainty index abated, but remains at \"historically high\" levels, according to NFIB.   Survey participants said finding qualified workers was their top business problem, exceeding taxes, regulations and poor sales.   Depressed inventories, a theme repeated in GDP and PMI data, remain an overhang. Although a majority of owners described their inventories as \"too low\" plans to invest in more inventory accumulation collapsed from record levels.   \"The recovery will remain uneven as long as we see state and local mandates that target business conditions and disproportionately affect small businesses,\" writes Bill Dunkelberg, chief economist at NFIB.   Oren Klachkin, lead U.S. economist at Oxford Economics, agrees.   \"Small businesses will face the greatest risk of failure as the recovery slows, especially if lawmakers don’t offer more aid,\" Klachkin says.    Separately, the Labor Department released revised data for third-quarter labor costs and productivity.   Labor costs    fell 6.6% in the quarter, shallower than the 8.9% previously reported, while productivity - or output per hour    - rose by 4.6%, slower than the originally-stated 4.9% increase.     \"The data have been especially volatile quarter-to-quarter reflecting the impact of Covid-19 on output, hours and compensation,\" says Rubeela Farooqi, chief U.S. economist at High Frequency Economics. \"The underlying trend in productivity will likely moderate from the current pace over coming quarters.\"   Caution kept buyers at bay in early trading.   All three major U.S. stock indexes are red, with losses in market-leading mega-cap tech and tech-adjacent shares putting the Nasdaq on course to snap its three-day record closing streak.   (Stephen Culp)   *****   PRODUCTIVITY BOUNCE ON THE HORIZON (0913 EST/1413 GMT)   Whether underpriced value is finally overtaking growth stocks remains a question on Wall Street, but as the go-go era tapers off, several years of stronger productivity could arrive to bolster equities, tap down inflation and hamper bond returns.   The observation comes from Jim Paulsen, chief investment strategist at the Leuthold Group in Minneapolis, who says while an imperfect relationship, more robust productivity often has followed periods of growth-style dominance after World War II.   But when value beats growth returns, weak productivity too often rules, Paulsen said in a note to investors.   It takes time before a new product's innovative attributes are fully communicated, disseminated, understood and implemented into business and households, Paulsen said. That's why there is a multi-year lag between a growth cycle and rising productivity.   Since 1947 as productivity rose, average inflation weakened and average bond returns declined. The usual negative linkage between inflation and bond returns is altered by productivity.   Overall economic growth tends to be healthy, forcing yields higher and bond returns lower. If the U.S. economy is poised for a period of superior productivity, investors should prepare for a challenging bond market, even with modest inflation, but a  rising equity market, he said.   The future power of U.S. core capital goods orders after they recently surged to an all-time record during a pandemic should not be underestimated, Paulsen said.   (Herbert Lash)   *****   S&P 500: FORK IN THE SKY? (0845 EST/1345 GMT)   As the S&P 500 index    attempts to forthrightly thrust above a significant resistance barrier  , the Northern Hemisphere's winter solstice is just over the horizon. Thus, it may shortly become clear whether the benchmark index is on the verge of a moon-shot to fresh records, or if the solstice's orb of influence will coincide with another major reversal.    Proponents of Gann Theory, or methods of technical analysis developed by trader W.D. Gann, may look for either acceleration of the prevailing trend, or a reversal, around the summer and winter solstices, as well as the fall and spring equinoxes.   Looking back over the past 2 years or so there has been interesting market action around these events. So far in 2020, these dates have all coincided with then end of periods of significant decline. (Click on chart below)   The 2020 spring equinox took place on Thursday, March 19, at 11:49 PM EDT. Two trading days later, the S&P 500 put in a surprise bottom that ended the more than 30% February/March bear market.   The summer solstice occurred on Saturday, June 20, at 5:43 PM EDT. Earlier that week, the SPX abruptly ended what was a more than 8% one-week slide.   The fall equinox took place on Tuesday, September 22 at 09:30 AM EDT. Just one day later, the SPX ended what was essentially a 10% correction from its early September high.   The coming solstice happens at 5:02 AM EST on December 21st. It now remains to be seen if around this date, the SPX will accelerate higher, or succumb to gravity.   Meanwhile, amid the pitch and yaw, there are signs of an overheated market  , permeated by great complacency . That said, advance/decline lines are still providing tailwinds.     (Terence Gabriel)   *****   FOR TUESDAY'S LIVE MARKETS' POSTS PRIOR TO 0845 EST/1345 GMT - CLICK HERE:      <^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^ SPX12082020F     NFIB     Productivity and labor costs     FANGECO12082020       ^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^^>(Terence Gabriel is a Reuters market analyst. The views expressed are his own)","news_type":1,"symbols_score_info":{"JKS":0.9,"SCO":0.6,"DWT":0.6,"QNETCN":0.6,"GOOGL":0.9,"DDM":0.6,"TSLA":0.9,"DXD":0.6,"USO":0.6,"DJX":0.6,"SQQQ":0.6,"DOG":0.6,"NIO":0.9,"SDOW":0.6,".DJI":0.9,".SPX":0.9,"AAPL":0.9,"TQQQ":0.6,"03086":0.6,"FB":0.9,"QQQ":0.6,"TWTR":0.9,"09086":0.6,"09988":0.9,"SPWR":0.9,".IXIC":0.9,"DDG":0.6,"QLD":0.6,"AMZN":0.9,"UCO":0.6,"NVDA":0.9,"DUG":0.6,"QID":0.6,"BIDU":0.9,"NFLX":0.9,"UDOW":0.6,"PSQ":0.6}},"isVote":1,"tweetType":1,"viewCount":1170,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}